Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Miles' Nisocor

Executive Summary

Miles' Nisocor: Firm considering outlicensing the calcium channel blocker extended-release nisoldipine, which was approved Feb. 2. Miles says it is "reviewing various commercial options in addition to directly marketing Nisocor," including copromotion and out-licensing. Nisocor was given a "1S" rating by FDA, designating a new molecular entity receiving a standard review. The NDA (20-356) for Nisocor was originally submitted on March 31, 1993. Miles resubmitted the application on Aug. 3, 1994 after receiving a "not approvable" letter from FDA in March 1994. Reasons for rejecting the initial application cited by the agency included inadequate stability data to establish shelf-life of the product and the lack of a stereochemical identity test to demonstrate that the drug is a racemic mixture. Nisocor was approved in tablet strengths of 10 mg, 20 mg, 30 mg and 40 mg...

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts